| 主权项 |
1. A pharmaceutical composition comprising a RecA inhibitor, and at least one physiologically acceptable carrier or excipient, wherein the composition further comprises at least one antibiotic and wherein the RecA inhibitor interacts directly with the RecA protein and wherein the RecA inhibitor is selected from the group consisting of: amentoflavone, hinokiflavone, isorhamnetin, maclurin, quercetagetin, quercetin dehydrate, 3,7,4′-trihydroxyflavone, theaflavin or a compound of formula (I) or formula (II) or pharmaceutical acceptable salts thereof or combinations thereof, wherein the compound of formula (I) has the following structure: wherein: X is oxygen, sulfur, or N(R); n is 0 to 4; R1 is hydrogen, or an optionally substituted group selected from a C1-6 aliphatic group, a monocyclic 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a bicyclic 8-10 membered saturated, partially unsaturated, or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R2 is independently halogen, R3, OR3, SR3, N(R3)2, C(O)R3, C(O)OR3, NR3C(O)R3, C(O)NR3, SO2R3 NR3SO2R3 SO2N(R3)2; each R3 is independently hydrogen or an optionally substituted group selected from a C1-6 aliphatic group, a monocyclic 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a bicyclic 8-10 membered saturated, partially unsaturated, or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Q is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 0-2 methylene units of Q are independently replaced by —O—, —NR—, —S—, —OC(O)—, —C(O)O—, —C(O)—, —SO—, —SO2—, —NRSO2—, —SO2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, or —NRC(O)O—; each R is independently hydrogen or an optionally substituted aliphatic group; Rx is R or OR; and Ring A is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and wherein the compound of formula (II) has the following structure: wherein: Cy1 is a an optionally substituted 5-6 membered aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; L1 is a valence bond, a C1-6 bivalent saturated, unsaturated, straight or branched hydrocarbon chain, —N(R)—, —N(R)SO2—, —N(R)SO2N(R)—, —N(R)C(O)—, —C(O)N(R)—, or —N(R)C(O)N(R)—; each R is independently hydrogen or an optionally substituted C1-6 aliphatic group; Cy2 is an optionally substituted 6-membered aryl ring having 0-2 nitrogen atoms, an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 5-membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; L2 is a C1-6 bivalent saturated, unsaturated, straight or branched hydrocarbon chain, —CH2CH2C(═W)N(R)N(R)C(═W)—, —N(R)C(═W)N(R)C(═W)C(R)2W—, —C(═W)N(R)N(R)C(═W)N(R)—, —C(═W)N(R)N(R)C(═W)N(R)CH═CH2, or —C(═W)N(R)C(═W)N(R)—, wherein each W is independently oxygen or sulfur; and Cy3 is an optionally substituted 6-membered aryl ring having 0-2 nitrogen atoms. |
